GlaxoSmithKline Price Target Cut to GBX 1,650 by Analysts at Jefferies Group (GSK)

Share on StockTwits

Research analysts at Jefferies Group lowered their target price on shares of GlaxoSmithKline (LON:GSK) from GBX 1,750 ($28.71) to GBX 1,650 ($27.07) in a report released on Wednesday, Analyst Ratings Network.com reports. The firm currently has a “hold” rating on the stock. Jefferies Group’s target price suggests a potential upside of 1.23% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Citigroup Inc. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Wednesday. They now have a GBX 1,810 ($29.70) price target on the stock. Separately, analysts at Panmure Gordon reiterated a “hold” rating on shares of GlaxoSmithKline in a research note on Thursday, February 6th. They now have a GBX 1,750 ($28.71) price target on the stock. Finally, analysts at UBS AG reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday, February 6th. They now have a GBX 1,650 ($27.07) price target on the stock. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company’s stock. GlaxoSmithKline currently has an average rating of “Hold” and an average target price of GBX 1,716.19 ($28.16).

GlaxoSmithKline (LON:GSK) opened at 1643.00 on Wednesday. GlaxoSmithKline has a 52 week low of GBX 1444.50 and a 52 week high of GBX 1816.00. The stock has a 50-day moving average of GBX 1606. and a 200-day moving average of GBX 1617.. The company’s market cap is £78.716 billion.

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Sovaldi Sales at Gilead Key to Earnings in First Quarter
Sovaldi Sales at Gilead Key to Earnings in First Quarter
Rubin Hurricane Carter Dead at Age 76
Rubin Hurricane Carter Dead at Age 76
Teva Denied Request for Patent Relief
Teva Denied Request for Patent Relief
Craze of Oil Swishing Hits the U.S.
Craze of Oil Swishing Hits the U.S.
Twelve Killed in Single Deadliest Avalanche on Mount Everest
Twelve Killed in Single Deadliest Avalanche on Mount Everest
Profit at American Express Exceeds Estimates
Profit at American Express Exceeds Estimates


Leave a Reply

 
© 2006-2014 WKRB News. Subscribe Subscribe